Marty Huber 의 보수는 Mersana Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$135m
Dec 31 2023	US$3m	US$194k	-US$172m
Sep 30 2023	n/a	n/a	-US$197m
Jun 30 2023	n/a	n/a	-US$215m
Mar 31 2023	n/a	n/a	-US$213m
Dec 31 2022	US$163k	n/a	-US$204m
Sep 30 2022	n/a	n/a	-US$208m
Jun 30 2022	n/a	n/a	-US$194m
Mar 31 2022	n/a	n/a	-US$183m
Dec 31 2021	US$290k	n/a	-US$170m
Sep 30 2021	n/a	n/a	-US$150m
Jun 30 2021	n/a	n/a	-US$127m
Mar 31 2021	n/a	n/a	-US$106m
Dec 31 2020	US$303k	n/a	-US$88m

보상 대 시장: Marty 의 총 보상 ($USD 3.04M )은 US 시장( $USD 1.62M ).

보상과 수익: 회사가 수익성이 없는 동안 Marty 의 보상이 증가했습니다.

CEO

Marty Huber (63 yo)

less than a year

테뉴어

US$3,044,085

보상

Dr. Martin H. Huber, also known as Marty, M.D., is President and Chief Executive Officer at Mersana Therapeutics, Inc. since September 2023. He served as President and Head of R&D at Xilio Therapeutics, In...

리더십 팀

이름	위치	테뉴어	보상	소유권
Martin Huber	President	less than a year	US$3.04m	데이터 없음
Brian DeSchuytner	Senior VP	4.9yrs	US$1.74m	0.045% $ 109.6k
Timothy Lowinger	Senior VP and Chief Science & Technology Officer	16.3yrs	US$1.69m	0.16% $ 400.6k
Alejandra Carvajal	Senior VP	3.2yrs	US$1.61m	0.022% $ 55.1k
Mohan Bala	Senior VP & Chief Development Officer	2.7yrs	US$1.58m	0.011% $ 28.2k
Mikhail Papisov	Co-Founder	no data	데이터 없음	데이터 없음
Ashish Mandelia	Chief Accounting Officer	4.8yrs	데이터 없음	0.021% $ 52.2k
Jason Fredette	Senior Vice President of Investor Relations & Corporate Communications	no data	데이터 없음	데이터 없음
Chuck Miller	Senior Vice President of Regulatory Affairs	3.8yrs	데이터 없음	데이터 없음
Marc Damelin	Exe. Director and Head of Biology	no data	데이터 없음	데이터 없음

3.8yrs

평균 재임 기간

54.5yo

평균 연령

경험이 풍부한 관리: MRSN 의 관리팀은 경험 ( 3.8 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Martin Huber	President	4.2yrs	US$3.04m	데이터 없음
David Mott	Independent Chairman	11.9yrs	US$329.93k	0.48% $ 1.2m
Peter Kiener	Member of the Scientific Advisory Board	no data	데이터 없음	데이터 없음
Lawrence Alleva	Independent Director	6.8yrs	US$308.93k	0.0017% $ 4.3k
Willard Dere	Independent Director	6.3yrs	US$305.43k	0.020% $ 49.7k
Kristen Hege	Independent Director	7.8yrs	US$293.43k	0% $ 0
Anna Protopapas	Director	9.3yrs	US$4.65m	0.34% $ 846.3k
Andrew A. Hack	Independent Director	7.4yrs	US$297.43k	0% $ 0
Misti Ushio	Board Observer	no data	데이터 없음	데이터 없음
Howard Burris	Member of the Scientific Advisory Board	no data	데이터 없음	데이터 없음
Allene Diaz	Independent Director	3.3yrs	US$294.93k	0% $ 0
K. Wittrup	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음

7.1yrs

평균 재임 기간

60.5yo

평균 연령

경험이 풍부한 이사회: MRSN 의 이사회는 경험(평균 재직 기간 7.1 년)으로 간주됩니다.

Mersana Therapeutics 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Mersana Therapeutics, Inc., Annual General Meeting, Jun 11, 2024

Director notifies of intention to sell stock

Mersana Therapeutics, Inc. Announces Chief Executive Officer Changes

Insufficient new directors

President exercised options and sold US$100k worth of stock

Chief Science & Technology Officer exercised options to buy US$230k worth of stock.

Recent updates

Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) 25% Dip In Price Shows Sentiment Is Matching Revenues

Mersana Therapeutics: On Hold While Waiting For Any Positive News

First quarter 2024 earnings released: US$0.16 loss per share (vs US$0.52 loss in 1Q 2023)

Mersana Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

Mersana Therapeutics, Inc., Annual General Meeting, Jun 11, 2024

Investors Don't See Light At End Of Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Tunnel And Push Stock Down 33%

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Mersana Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Shares Bounce 26% But Its Business Still Trails The Industry

Mersana Therapeutics, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Director notifies of intention to sell stock

Mersana Therapeutics: A Bottom-Feeding Gamble Of A Stock

Mersana Therapeutics, Inc. Announces Business Updates

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

Mersana Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Here's Why Mersana Therapeutics (NASDAQ:MRSN) Can Manage Its Debt Despite Losing Money

Mersana Therapeutics, Inc. Announces Chief Executive Officer Changes

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates upgraded to US$1.72 loss

Mersana Therapeutics, Inc. Announces Topline Data from UPLIFT Clinical Trial in Patients with Platinum-Resistant Ovarian Cancer and Strategic Reprioritization

Price target decreased by 31% to US$10.50

Mersana Therapeutics Announces Partial Clinical Hold on UP-NEXT and UPGRADE-A Clinical Trials

Is Mersana Therapeutics (NASDAQ:MRSN) A Risky Investment?

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Price target decreased by 11% to US$15.00

Full year 2022 earnings released: US$2.18 loss per share (vs US$2.41 loss in FY 2021)

Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Intrinsic Value Is Potentially 22% Below Its Share Price

Mersana Therapeutics, Inc. Initiates Expansion Portion of Upgrade-A Combination Clinical Trial in Platinum-Sensitive Ovarian Cancer

Mersana Therapeutics, Inc. Announces Initiation of Phase 1 Trial of XMT -2056 in Her2-Expressing Tumors

President exercised options and sold US$100k worth of stock

Consensus revenue estimates increase by 20%

Chief Science & Technology Officer exercised options to buy US$230k worth of stock.

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Mersana Therapeutics, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Mersana Therapeutics Announces Completion of Enrollment in UPLIFT, a Single-Arm Registrational Trial of Upifitamab Rilsodotin (UpRi) in Platinum-Resistant Ovarian Cancer

Mersana Therapeutics Inc. Announces Launch of Oncology Facets

Mersana gains as FDA grants fast track status for breast cancer drug

Mersana Therapeutics, Inc. Announces Initiation of Phase 1 Trial of XMT-1660 in Breast, Endometrial and Ovarian Cancers

Consensus revenue estimates increase by 725%

Mersana Therapeutics: Savvy Partnering But Further Progress Is Needed

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$17.75

Consensus revenue estimates increase by 12%

Mersana Therapeutics, Inc. Announces FDA Grant of Orphan Drug Designation to Xmt-2056 for the Treatment of Gastric Cancer

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Mersana Therapeutics, Inc. to Report Q1, 2022 Results on May 09, 2022

Mersana Therapeutics, Inc., Annual General Meeting, Jun 09, 2022

Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1660, XMT-2056 and the Immunosynthen Platform at AACR Annual Meeting

Consensus revenue estimates increase by 93%

Consensus revenue estimates increase by 17%

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Taking The Measure Of Mersana Therapeutics

Chief Science & Technology Officer exercised options to buy US$268k worth of stock.

Third quarter 2021 earnings released: US$0.63 loss per share (vs US$0.33 loss in 3Q 2020)

Price target decreased to US$24.00

Price target decreased to US$24.00

Chief Manufacturing Officer Michael Kaufman has left the company

Consensus revenue estimates fall to US$256.2k

First half 2021 earnings released: US$1.09 loss per share (vs US$0.68 loss in 1H 2020)

President exercised options and sold US$513k worth of stock

Mersana: ADC Developer With New INDs, Sufficient Cash, And XMT-1536 Progress

It's Unlikely That The CEO Of Mersana Therapeutics, Inc. (NASDAQ:MRSN) Will See A Huge Pay Rise This Year

Chief Science & Technology Officer notifies of intention to sell stock

Consensus forecasts updated

First quarter 2021 earnings released: US$0.50 loss per share (vs US$0.35 loss in 1Q 2020)

Consensus forecasts updated